Journal of Lipid Research, Vol 30, 1691-1701, Copyright © 1989 by Lipid Research, Inc.

ARTICLES

Accumulation of an apoE-poor subfraction of very low density lipoprotein in hypertriglyceridemic men

AJ Evans, MW Huff and BM Wolfe
Department of Medicine, University of Western Ontario, London, Canada.

Studies were undertaken to investigate the mechanism of the marked accumulation of an apoE-poor very low density lipoprotein (VLDL) subfraction in untreated Type IV and IIb hypertriglyceridemic subjects. Heparin-Sepharose chromatography was used to separate large VLDL (Sf 60- 400) from fasted subjects, into an apoE-poor, unbound fraction and an apoE-rich, bound fraction. As a percent of total VLDL protein, the apoE- poor fraction comprised 40 +/- 4% of total VLDL in hypertriglyceridemic subjects versus 25% in normal subjects. Compared to the apoE-rich, bound fraction, this apoE-poor material was found to have a 5-fold lower ratio of apoE to apoC (0.20 +/- 0.06 vs 0.91 +/- 0.18, P less than 0.005), but a 1.5-fold higher ratio of triglyceride to protein (11.41 +/- 0.85 vs 7.97 +/- 0.77, P less than 0.01). In addition, the apoE-poor fraction was found to be enriched 2-fold in apoB-48 (10.30 +/- 2.41% vs 5.73 +/- 1.59% of total apoB, P less than 0.005) compared to the apoE-rich fraction, suggesting that the apoE-poor fraction contains more chylomicron remnants. The amount of this apoE-poor VLDL was markedly reduced following a reduction in VLDL triglyceride levels (a decrease from 40 +/- 4% to 21 +/- 2% of VLDL protein following a 50% reduction in VLDL triglyceride levels). The large VLDL from Type I, III, and V hyperlipoproteinemic subjects subfractionated using heparin- Sepharose showed an equal distribution of apoE between the two fractions in contrast with the Type IV and IIb subjects. The separation of VLDL from Type I, III, and V subjects using heparin-Sepharose involves a mechanism other than apoE binding. Separation in the latter likely results from apoB-100 binding to heparin, as opposed to apoE binding of VLDL from Type IV and IIb subjects.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. C. Whitman, C. A. Argmann, C. G. Sawyez, D. B. Miller, R. A. Hegele, and M. W. Huff Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-{gamma} J. Lipid Res., June 1, 1999; 40(6): 1017 - 1028. [Abstract] [Full Text]

				S. C. Whitman, S. L. Hazen, D. B. Miller, R. A. Hegele, J. W. Heinecke, and M. W. Huff Modification of Type III VLDL, Their Remnants, and VLDL From ApoE-Knockout Mice by p-Hydroxyphenylacetaldehyde, a Product of Myeloperoxidase Activity, Causes Marked Cholesteryl Ester Accumulation in Macrophages Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1238 - 1249. [Abstract] [Full Text] [PDF]

				S. C. Whitman, C. G. Sawyez, D. B. Miller, B. M. Wolfe, and M. W. Huff Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL J. Lipid Res., May 1, 1998; 39(5): 1008 - 1020. [Abstract] [Full Text]

				C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text]

				C. Grunfeld, W. Doerrler, M. Pang, P. Jensen, K. H. Weisgraber, and K. R. Feingold Abnormalities of Apolipoprotein E in the Acquired Immunodeficiency Syndrome J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3734 - 3740. [Abstract] [Full Text] [PDF]

				S. C. Whitman, D. B. Miller, B. M. Wolfe, R. A. Hegele, and M. W. Huff Uptake of Type III Hypertriglyceridemic VLDL by Macrophages Is Enhanced by Oxidation, Especially After Remnant Formation Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1707 - 1715. [Abstract] [Full Text]

				T. Murakami, S. Michelagnoli, R. Longhi, G. Gianfranceschi, F. Pazzucconi, L. Calabresi, C. R. Sirtori, and G. Franceschini Triglycerides Are Major Determinants of Cholesterol Esterification/Transfer and HDL Remodeling in Human Plasma Arterioscler. Thromb. Vasc. Biol., November 1, 1995; 15(11): 1819 - 1828. [Abstract] [Full Text]

				V. Clavey, S. Lestavel-Delattre, C. Copin, J. M. Bard, and J. C. Fruchart Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 963 - 971. [Abstract] [Full Text]